Your browser doesn't support javascript.
loading
Henoch-Schönlein Purpura Following the First Dose of COVID-19 Viral Vector Vaccine: A Case Report.
Sirufo, Maria Maddalena; Raggiunti, Martina; Magnanimi, Lina Maria; Ginaldi, Lia; De Martinis, Massimo.
Afiliação
  • Sirufo MM; Department of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
  • Raggiunti M; Allergy and Clinical Immunology Unit, AUSL 04 Teramo, 64100 Teramo, Italy.
  • Magnanimi LM; Department of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
  • Ginaldi L; Allergy and Clinical Immunology Unit, AUSL 04 Teramo, 64100 Teramo, Italy.
  • De Martinis M; Department of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
Vaccines (Basel) ; 9(10)2021 Sep 25.
Article em En | MEDLINE | ID: mdl-34696186
ABSTRACT
A 76 year-old female came to our observation one week after the vaccination with ChAdOx1 nCoV-19 AZD1222 for the onset of purpuric rash on her gluteal and legs regions associated with coxalgia and episodes of macrohaematuria. Henoch-Schönlein purpura (HSP) was diagnosed on the basis of the revised criteria developed by the European League Against Rheumatism, the Paediatric Rheumatology International Trials Organization, and the Paediatric Rheumatology European Society (EULAR/PRINTO/PRES). HSP is a common IgA-mediated small vessel vasculitis, typical of childhood, that affects several systems and is characterized by a tetrad of dermatological, abdominal, joint, and renal manifestations. The Etiology of HSP is not completely understood, but it was observed following upper respiratory tract infections, medications, vaccinations, and malignancies. HSP has previously been reported following immunization with various vaccines, mostly within 12 weeks post, suggesting a possible correlation. To our knowledge, this is the first report of the possible association between COVID-19 ChAdOx1 nCoV-19 AZD1222 and the onset of HSP in a previously healthy woman. No similar cases were reported amongst 23.848 participants in the ChAdOx1 nCoV-19 AZD1222 trial.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Vaccines (Basel) Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Vaccines (Basel) Ano de publicação: 2021 Tipo de documento: Article